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ABSTRACT
Background. Standard treatment for localized soft tissue
sarcoma (STS) is resection plus adjuvant radiotherapy
(RTx). In approximately 10% of cases, resection would
cause severe loss of function or even require amputation
because of the extent of disease. Isolated limb perfusion
(ILP) with tumor necrosis factor alpha (TNF-a) and mel-
phalan can achieve regression of the tumor, facilitating
limb-saving resection. RTx improves local control but may
lead to increased morbidity.
Methods. In our database of over 500 ILPs, 122 patients
with unifocal STS were treated by ILP followed by limb-
sparing surgery. All included patients were candidates for
amputation.
Results. Surgery resulted in 69 R0 resections (57%), and
in 53 specimens (43%) resection margins contained
microscopic evidence of tumor (R1). Histopathological
examination revealed [50% ILP-induced tumor necrosis in
59 cases (48%). RTx was administered in 73 patients
(60%). Local recurrence rate was 21% after median follow-
up of 31 months (2–182 months). Recurrence was signifi-
cantly less in patients with [50% ILP-induced necrosis
versus B50% necrosis (7% vs. 33%, P = 0.001). A similar
significant correlation was observed for R0 versus R1
resections (15% vs. 28%, P = 0.04). In 36 patients with R0
resection and [50% necrosis, of whom 21 were spared
RTx, no recurrences were observed during follow-up.
Conclusions. In patients with locally advanced primary
STS, treated with ILP followed by R0 resection, and
with [50% ILP-induced necrosis in the resected specimen,
RTx is of no further benefit.
Soft tissue sarcomas (STSs) are a heterogeneous group
of rare malignancies. In the USA, 8,680 new cases of STS
are diagnosed annually, of which approximately 60% are
located in the extremities.1 STSs are associated with early
metastasis and a high disease-specific mortality rate of
approximately 50%. Moreover, STS of the extremity is
often large at time of presentation, making local resection
and tumor control difficult.1 Local control may require
extensive surgery, resulting in loss of limb function or
amputation in 10% of cases. Amputation, however, is not
associated with prolonged survival, because survival is
determined by the occurrence of systemic disease.2,3 Since
amputation has no beneficial effect on survival, growing
interest in limb-salvaging techniques has arisen. Isolated
limb perfusion (ILP) is a technique that results in perfusion
of a tumor with high concentrations of tumor necrosis
factor alpha (TNF-a) and melphalan under hyperthermic
conditions. Following introduction of the technique in the
early 1990s, Eggermont et al.4 reported encouraging results
in a large European multicenter study. Subsequent studies
showed high local response and limb salvage rates and
acceptable local and systemic toxicity.5
Currently, use of ILP followed by resection and RTx is an
established strategy for limb salvage in Europe. Long-term
morbidity has been described after ILP.6 A contributing
factor to morbidity is adjuvant RTx.6 However, whether
adjuvant RTx is necessary for all patients treated with ILP
remains unclear. The aim of this study is to identify a specific
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group of patients in whom adjuvant RTx was of no further
benefit for tumor control. All patients in our hospital
undergoing ILP for unifocal STS of the extremity followed
by local resection were identified. Subsequently, we deter-
mined whether patients with STS of the extremity may be
spared adjuvant RTx under specific circumstances.
PATIENTS AND METHODS
Patients
From August 1991 to March 2009, 511 ILPs were per-
formed in our hospital. These 511 cases comprised 168
melanomas, 306 STS, and 37 miscellaneous malignancies
(Fig. 1).
ILP was the treatment strategy in 74 cases of multiple
STS, while 232 patients were treated for unifocal disease.
In this retrospective study we evaluated all 122 consecutive
ILPs (in 120 patients) for unifocal STS followed by limb-
sparing surgical resection. The minimal tumor–node–
metastasis (TNM) stage was IB, while the vast majority of
STS was staged as IIB. Liposarcoma was the most common
treated type of STS in our study, of which 3 were well
differentiated, 2 were dedifferentiated, 7 were pleomor-
phic, and 16 were of myxoid subtype. Patient characteris-
tics are summarized in Table 1.
Perfusion
The technique of ILP with TNF-a and melphalan has
been described previously.4,5 Briefly, the procedure is
performed with patients under general anesthesia. After
heparinization, a targeted blood circuit is isolated by
clamping and cannulation of the major artery and vein and
connection to an oxygenated extracorporeal circuit. A
tourniquet compresses collateral vessels and prevents
leakage. Using a precordial scintillation probe to detect
technetium-labeled albumen, leakage is monitored for the
length of the procedure. Patients underwent ILP via axil-
lary (n = 9), brachial (n = 19), iliac (n = 54), femoral














FIG. 1 Inclusion flow chart






B50 years 56 45.9
[50 years 66 54.1
Size
\5 cm 20 16.4
5–10 cm 34 27.9







Upper arm 8 6.6
Elbow 5 4.1
Lower arm 10 8.2
Wrist or hand 5 4.1
Upper leg 46 37.7
Knee 20 16.4
Lower leg 22 18.0
Ankle or feet 6 4.9
Histology
Liposarcoma 28 23.0
Synovial sarcoma 24 19.7
HGPS NOS 16 13.1
Leiomyosarcoma 12 9.8







HGPS NOS high-grade pleomorphic sarcoma not otherwise specified
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A dose of 1–3 mg (arm) or 1–4 mg (leg) recombinant
TNF-a (Boehringer Ingelheim GmbH, Ingelheim/Rhein,
Germany) was injected as a bolus once the temperature of
the limb reached 38C. Subsequently, 13 mg/l (arm) or
10 mg/l (leg) melphalan (L-PAM; Alkeran, Burroughs
Wellcome Ltd., London, UK) was administered 30 min
after the limb temperature reached 38–39.5C. The median
dose of TNF-a administered was 4.0 mg (mean 3.2 mg,
range 1–4 mg), while the median dose of melphalan was
75 mg (mean 79.8 mg, range 18–160 mg). Several studies
reported successful use of reduced doses of TNF-a in ILP
for STS with comparable local recurrence rates and no
systemic toxicity.7,8 Thereafter, perfusion was executed
with 1 mg TNF-a in the arm and 2 mg in the leg. Conse-
quently, since 2005 the median dose of TNF-a has been
2.0 mg (mean 2.09 mg, range 1–3 mg). After 90 min of
perfusion, the limb was washed out with 1 l (arm) to 4 l
(Iliac perfusion) physiological saline solution and 6%
dextran (Macrodex Pharmacia, Uppsala, Sweden). Patients
were observed in intensive care unit (ICU) for one night.
Median length of hospital stay was 8 days (mean 11 days,
range 2–136 days).
Clinical response was defined using clinical findings and
magnetic resonance imaging (MRI). Complete response
(CR) was defined as complete remission of tumor tissue,
while partial response (PR) was defined as 51–99%
remission. No change (NC) was defined as 0–50% remis-
sion. Clinical evidence of new lesions or growth of the
tumor was defined as progressive disease (PD).
Local Control
Whenever the response of the tumor to ILP appeared to
facilitate local resection without major limb function loss,
local resection was attempted. Local resection was per-
formed at median of 84 days (mean 91 days, range
14–260 days) after ILP. Margine status of the resection
was defined using the criteria according to Pisters et al.9 In
each surgical specimen the peripheral margins were inked.
A microscopically positive (R1) margin was defined as
unequivocal tumor extension to the inked margin on per-
manent section. Cases in which tumor was close to but did
not reach the inked margin were considered to have
microscopically negative margins (R0). The percentage of
the tumor that was necrotic due to ILP was estimated by the
pathologist by macroscopic inspection and microscopic
confirmation. Two categories were defined: 51–99%
necrosis of the tumor and 0–50% necrosis of the tumor.
Radiotherapy
Adjuvant RTx was administered to 73 (60%) patients,
while 49 (40%) patients did not receive RTx. Like all other
decisions concerning STS, decisions on the subject of
adjuvant RTx were made in a multidisciplinary board
containing a surgical oncologist, a medical oncologist, a
radiation oncologist, a pathologist, and a radiologist.
Before 1998, there was little evidence that adjuvant RTx
was beneficial after local resection of STS. Since Olieman
et al.10 reported improved outcome after adjuvant RTx in
1998, our center has administered significantly more RTx
(P = 0.04). Reasons for refraining from administering
adjuvant RTx after 1998 are summarized in Table 2.
RESULTS
Clinical Response
Clinical response after ILP was complete in five cases
(4%). PR was obtained in 80 patients (66%), NC in 35
patients (29%), and PD in 1 patient (1%). Clinical response
was not assessed in one patient (1%) for unknown reason.
Local Control
Results are summarized in Table 3. Local resection of
the STS resulted in R0 resection in 69 patients (57%),
while 53 (43%) patients had R1/R2 resection. The overall
local recurrence rate was 21% (25 patients) after median
follow-up of 31 months (mean 48 months, range
2–182 months); 5-year recurrence-free survival (RFS) was
75% (±5% standard error, SE). If recurrence occurred,
median time to recurrence was 15 months (mean
27 months, range 3–170 months). After R0 resection,
5-year RFS was 80%, while patients with R1 resection had
5-year RFS of 72%. This difference reached significance
(P = 0.04, Fig. 2).The local recurrence rate was 15% in
the R0 group (10 patients), while the R1 group had a local
recurrence rate of 28% (15 patients). In 13 cases (11%),
amputation, after limb-saving resection, was deemed nec-
essary during follow-up. Median time between limb-
sparing resection and amputation was 29 months (mean
25 months, range 2–60 months). Consequently, the limb
salvage rate was 89%.
TABLE 2 Reasons for no RTx after 1998
N %
Systemic disease 8 40
Joint/hand/foot 3 15
Age/comorbidity 2 10
Refused by patient 1 5
Reason not specified 6 30
Total 49 100.0
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Histopathological examination of the resection speci-
mens revealed [50% ILP-induced tumor necrosis in 59
cases (48%). In 63 (52%) cases the response to ILP was
50% or less. Patients with [50% necrosis in specimen after
resection had 5-year RFS of 92%, while patients
with B50% necrosis had 5-year RFS of 61%. As can be
seen in Fig. 3, this difference was significant (P = 0.001).
In the group with [50% necrosis of the tumor, the local
recurrence rate was 7% (4 cases), compared with 33% (21
cases) in the group with B50% tumor necrosis. None of the
patients were treated with adjuvant systemic chemotherapy
or any other treatment modality in the time interval
between ILP and resection. Combining these results we
could define a group of 43 patients (35%) with R0 resection
and [50% tumor necrosis, with a single case of local
recurrence. This concerned a patient who was treated for
local recurrence. This female, aged 44 years, had no signs
of residual vital tumor in the resected specimen. Since the
tumor had been small and difficult to locate preoperatively,
the completeness of the resection was deemed doubtful.
Therefore, RTx was proposed, but refused by the patient. In
retrospect, we believe that the tumor was not resected
during surgery.
None of the patients with R0 resection and [50%
necrosis who were treated for primary STS (n = 36)
developed local recurrence. Patients with R0 resection but
less than 50% necrosis of tumor (n = 26) showed recur-
rence in nine cases (35%).
The local recurrence rate for patients treated with
adjuvant RTx was 23%, while patients not treated with
RTx had local recurrence in eight cases (16%). Whether
patients with R0 resection had RTx was not based on main
tumor characteristics (Table 4).
DISCUSSION
Our results suggest that patients with primary and uni-
focal STS of the extremity, in whom R0 resection is
achieved after successful ILP (induction of [50% necro-
sis), may not benefit from adjuvant RTx. In these patients,
the recurrence rate was 0%. Patients treated for recurrence
TABLE 3 Results for all STS
R Histology (%) N Recurrence Recurrence rate (%)
No RTx R0 B50 7 1 14.3
R0 [50 28 1a 3.6
R1 B50 8 4 50.0
R1 [50 6 2 33.3
Total 49 8 16.3
RTx R0 B50 19 8 42.1
R0 [50 15 0 0.0
R1 B50 29 8 27.6
R1 [50 10 1 10.0
Total 73 17 23.3
Total R0 69 10 14.5
R1 53 15 28.3
B50 63 21 33.3
[50 59 4 6.8
Total 122 25 20.5












































































FIG. 3 Local recurrence versus histopathological response
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of STS (n = 7), who had R0 resection and [50% tumor
necrosis, showed local recurrence in one case.
The overall local recurrence rate in our series was 21%,
which is in accordance with several other studies describ-
ing ILP as a limb-saving strategy for STS (11–34%), while
reported recurrence rates for primarily resectable STS
range from 10 to 27%.5,7,10–18
A CR rate of 4% seems low compared with the rate of 28%
in the multicenter trial published by Eggermont et al. or in
comparison with the latest studies of Bonvalot at al. (30%;
n = 100), Grabellus et al. (15%; n = 47), and Pennachioli
et al. (41%; n = 88).7,14–16 The discordance is due to
selection bias, since we only included patients with limb-
sparing surgery after ILP. The vast majorities of patients with
MRI-proven CR were not considered for resection and had
clinical follow-up for 10 years. Another bias was the
exclusion of multifocal tumors in general (Lev–Chelouche,
CR = 38, n = 53) or Stewart–Treves lymphangiosarcoma
(Lans et al., CR = 56%; n = 16), which are known to
respond well to ILP.19,20 With the introduction of the use of
TNF-a in ILP there was a substantial improvement in treat-
ment for nonresectable extremity STS.4,5,12,21,22 Nowadays
ILP with delayed resection is an established strategy for limb
salvage in Europe. Median time span between resection and
ILP was 84 days, which was within the range of previous
reports (42–117 days).22,23 Completeness of resection is an
important prognostic factor for local recurrence.14,17,18,24–26
After R0 or R1 resection in patients with over 50% tumor
necrosis, a local recurrence rate of only 7% was observed. Of
patients with B50% necrosis in resection specimen, 33%
had recurrence. This highly significant difference suggests
that the degree of ILP-mediated tumor necrosis might be an
even stronger prognostic factor for local recurrence and
supports the findings of Grabellus et al.14 that improved
margin status is achieved after ILP. In patients with R1
resection with [50% necrosis, 19% local recurrence was
observed. This is a notable improvement in comparison with
the large analysis (n = 1,041) of Pisters et al. who reported a
local recurrence rate of 40% for R1 resection of extremity
STS without ILP.18 Considering the larger proportion of
large tumors ([10 cm; 25 vs. 56%) in our series, this result is
more remarkable.
It could be argued that determining the degree of
necrosis may not necessarily reflect a therapy effect but
may be inherent tumor necrosis. Furthermore, macroscopic
evaluation is a subjective and therefore imprecise factor.
Considering the fact that tumor necrosis in untreated STS is
an independent unfavorable prognostic factor, it may be
assumed that the necrosis observed in ILP-treated sarcomas
is indeed therapy related and prognostically relevant.
Second, considering the broad categories defined for tumor
necrosis in grading systems (0, \50, and [50%) it is
highly unlikely that the degree of necrosis in single cases
falls near the cutoff point. Furthermore, in our experience
the pattern of necrosis in ILP-treated sarcomas, consisting
of large confluent areas of necrosis, is different from the
patch pattern of necrosis seen as spontaneous necrosis in
untreated sarcomas. Finally, the MRIs that were performed
before ILP showed central necrosis in only 7 (12%) of 59
cases with [50% ILP-induced necrosis.
The value of adjuvant RTx after ILP and resection is
still unclear. The beneficial effect of irradiation in limb-
saving surgery for STS was first demonstrated by Rosen-
berg et al.2 Despite reporting a significant decrease in STS
local recurrence after irradiation therapy, Yang et al.27
concluded that, in selected patients with low risk for
recurrence, irradiation should not be considered because of
important lifetime risk for complications. Other studies
claimed that adjuvant RTx in all cases had a significant
positive influence in obtaining local control.10,23
Complications of RTx should not be underestimated.
Hoven-Gonderie et al.28 reported that two-thirds of all
patients experienced serious late toxic problems after
combined treatment for STS. Major problems with wound
healing and continuous wound infections (8–14%) are
described in literature.29,30 Vascular damage (4–14%) is a
common long-term complication of RTx.6,30,31 Kalman
et al.32 described four cases of long-term vascular side-
effects in the axillary artery after mastectomy with adju-
vant RTx, 10–27 years after treatment. RTx may cause
neuropathy, especially when a boost is given.28,33
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Although radiation is effective in improving local con-
trol, several studies suggest that, after margin-free resection,
a subset of patients do not benefit from RTx.14,34,35 In a
prospective study, Pisters et al.9 reported that patients with
T1, R0-resected STS have acceptable long-term local con-
trol and may be spared the short- and long-term toxicity
of RTx.
In our series, patients were not randomized for adjuvant
RTx, so the conclusions based on our findings have to be
read with caution. Furthermore, with 36 patients in
18 years, the defined group that can be spared RTx is rel-
atively small. Further studies should be performed to
confirm these findings. Nevertheless, our results suggest
that patients with R0 resection combined with [50% ILP-
induced necrosis may be spared adjuvant RTx. The benefit
of adjuvant RTx after ILP followed by limb-sparing sur-
gery for this subset of patients seems limited. The added
morbidity, the lack of survival benefit, and the limited
effect on local recurrence should be discussed with these
patients.
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